Huaying Y. Wang
No. 255, Dong'An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
The features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype: a retrospective study in a large Chinese cohort.
Journal: Journal of cancer research and clinical oncology
Published: January 12, 2026
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).
Journal: Journal of ovarian research
Published: August 12, 2025
Fully-connected network-based prediction model for lymph node metastasis in clinical early-stage endometrial cancer: development and validation in two centers.
Journal: Frontiers in oncology
Published: May 13, 2025
Prevalence of hysterectomy in urban China and associations between metabolic disorders and hysterectomy: a multicenter population-based study involving over 9 million women.
Journal: BMC medicine
Published: April 24, 2025
CACNB1 alleviates mepivacaine‑induced myocardial ischemia/reperfusion injury by promoting Nrf2 nuclear translocation.
Journal: Molecular medicine reports
Published: January 09, 2025
Prognostic factors and optimal management approaches for stage IB uterine leiomyosarcoma: a retrospective analysis.
Journal: Journal of gynecologic oncology
Published: December 01, 2024
Constructing a prediction model for lymph node metastasis in patients with incidental finding of endometrial cancer based on Fully-Connected Network.
Journal: Journal of gynecologic oncology
Published: July 28, 2024
Deep cervical stromal invasion predicts poor prognosis in patients with stage II endometrioid endometrial cancer: a two-centered retrospective study.
Journal: Frontiers in oncology
Published: June 16, 2024
Clinical application of FIGO 2023 staging system of endometrial cancer in a Chinese cohort.
Journal: BMC cancer
Published: May 21, 2024
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.
Journal: BMC medicine
Published: March 08, 2024
Shanghai Gynecologic Oncology Group's consensus on the academic and industry's clinical trial types.
Shanghai Gynecologic Oncology Group's consensus on the academic and industry's clinical trial types.
Journal: Chinese medical journal
Published: February 02, 2024
Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 29, 2023
Last Updated: 09/26/2026